Bristol-Myers Squibb to Announce Results for First Quarter 2011 on April 28

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2011 on Thursday, April 28, 2011. During a conference call at 10:30 a.m. EDT on April 28, company executives will review financial information and will address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by dialing 913-312-0670, confirmation code: 5540965. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 2:00 p.m. EDT on April 28 through midnight EDT on May 12, 2011. The replay will also be available through http://investor.bms.com or by dialing 402-280-9013, confirmation code: 5540965.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb Company
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Banking  Finance  Communications  Public Relations/Investor Relations

MEDIA:

Logo
 Logo

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.